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Strategies to prevent pyrexia in patients with acute neurological injury may reduce second-
ary neuronal damage. The aim of this study was to determine the safety and efficacy of the
routine administration of 6 grams/day of intravenous paracetamol in reducing body temper-
ature following severe traumatic brain injury, compared to placebo.
Methods
Amulticentre, randomised, blind, placebo-controlled clinical trial in adult patients with trau-
matic brain injury (TBI). Patients were randomised to receive an intravenous infusion of
either 1g of paracetamol or 0.9% sodium chloride (saline) every 4 hours for 72 hours. The
primary outcome was the mean difference in core temperature during the study intervention
period.
Results
Forty-one patients were included in this study: 21 were allocated to paracetamol and 20 to
saline. The median (interquartile range) number of doses of study drug was 18 (17–18) in
the paracetamol group and 18 (16–18) in the saline group (P = 0.85). From randomisation
until 4 hours after the last dose of study treatment, there were 2798 temperature measure-
ments (median 73 [67–76] per patient). The mean ± standard deviation temperature was
37.4±0.5°C in the paracetamol group and 37.7±0.4°C in the saline group (absolute differ-
ence -0.3°C; 95% confidence interval -0.6 to 0.0; P = 0.09). There were no significant differ-
ences in the use of physical cooling, or episodes of hypotension or hepatic abnormalities,
between the two groups.
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Conclusion
The routine administration of 6g/day of intravenous paracetamol did not significantly reduce
core body temperature in patients with TBI.
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Introduction
Pyrexia, defined as temperature greater than 37°C[1–5], is common in patients with traumatic
brain injury (TBI) during the initial 72 hours following admission to the intensive care unit
(ICU)[6–10]. Pharmacological agents and physical interventions are commonly used to reduce
pyrexia in these patients[6, 7].
The rationale for reducing pyrexia is based on evidence from animal models of TBI that sug-
gest that normothermic conditions may be associated with improved histopathological and
neurobehavioural outcomes compared to hyperthermic conditions[11, 12]; from observational
studies that report that patients with TBI who develop pyrexia have a higher incidence of
adverse outcomes[8, 10, 13] compared to patients who do not develop pyrexia, and from clini-
cal studies that report that reduction of temperature may be associated with a reduction in
intracranial pressure[14–16]. There is uncertainty whether reducing or preventing pyrexia is
associated with improved patient-centred outcomes[17–21].
Paracetamol is widely used as an early antipyretic pharmacological agent after TBI[6, 7, 22,
23]. The mechanism of the anti-pyretic action of paracetamol is based on inhibition of prosta-
glandin synthesis within the central nervous system[24], including indirect actions of paraceta-
mol metabolites on cannabinoid[25] and vanilloid[26] receptors. Despite this common
practice, there is a paucity of high-quality evidence evaluating its efficacy and safety in this
patient population[17].
A previous phase II, randomised, placebo-controlled trial of paracetamol administered by
the enteral route in patients with acute ischaemic stroke reported that while 3g/day of paraceta-
mol did not reduce body temperature, 6g/day of paracetamol reduced body temperature by
0.3°C compared to placebo[27], without adverse effects. These observations were confirmed in
a subsequent phase III clinical trial that enrolled 1400 participants in a similar population[2].
Based on these data, we sought to determine the efficacy and safety of the early, routine
administration of 6g/day of intravenous paracetamol in reducing core body temperature in
patients with severe TBI compared to placebo.
Methods
Study oversight
We conducted an investigator-initiated, two-centre, parallel-group, blind, randomised, pla-
cebo-controlled trial. The Human Research and Ethics Committee of South Western Sydney
Area Health Service granted ethical approval for the study (approval number: 09/NEPEAN/43:
14/10/2009); prospective written consent from the patient’s substitute decision maker was
required and we obtained prospective written consent for all patients.
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design and conduct of the study; collection,
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or preparation, review, and approval of the
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Participants and study setting
Patients with an admission diagnosis of TBI admitted to the ICUs of two university-affiliated
trauma centres in Australia within 72 hours of injury were screened to meet the following
inclusion criteria: (i) age> 18 and< 65 years; (ii) non-penetrating TBI, defined by a brain
injury due to mechanical forces and the presence of haemorrhage, contusion, swelling, com-
pression of basal cisterns or herniation on cerebral CT scan; (iii) requirement for mechanical
ventilation (iv) serum alanine transferase level< 100 iU/l.
The exclusion criteria were: (i) the use of any pharmacological or physical intervention that
could modify temperature within the previous 6 hours or clinician intent to modify body tem-
perature using any pharmacological or physical intervention; (ii) body temperature< 36°C
or> 38.9°C; (iii) pre-specified risk factors for paracetamol toxicity (S1 Table) (iv) TBI not
expected to require intensive care management for 72 hours after randomisation; (v) GCS of 3
with fixed dilated pupils, or moribund patient expected to die within 24 hours; (vi) confirmed
or suspected pregnancy.
Treatment allocation and blinding
Randomisation was conducted using a computer-generated list of random numbers (SAS v9.2)
prepared by an investigator with no clinical involvement in the patient and no access to trial
data until the data analysis was complete. The study was stratified according to participating
institution in a 1:1 ratio using permuted block sizes of 4, with investigators and clinicians
unaware of block size.
At each study site, independent individuals who were not involved in the study or clinical
activities, prepared study solutions according to randomisation codes; the study solutions were
blinded, by the use of an opaque shroud to conceal differences in product packaging, although
the two solutions were macroscopically indistinguishable.
Eligible patients were randomised to receive an intravenous infusion of 100mls of either
1-gram of intravenous paracetamol (Perfalgan, Bristol Myers Squib, Mulgrave, Victoria, Aus-
tralia) or 0.9% sodium chloride (Pfizer, West Ryde, New South Wales, Australia) (saline) over
30 minutes, every four hours, for 72 hours.
Each dose of intravenous paracetamol solution contained mannitol (3.85g), cysteine hydro-
chloride, sodium phosphate dihydrate, sodium hydroxide and hydrochloric acid.
Participants, healthcare providers, data collectors, outcome adjudicators, data analysts and
investigators were all unaware of treatment allocation during the conduct of the study.
Study treatment and process measures
As 6g/day of paracetamol is higher than the recommended maximum daily dose of 4g/day
daily, we monitored hepatic toxicity daily during study treatment and at 7 days after com-
mencement of study treatment.
Study treatment would be ceased if serum alanine transferase exceeded 250 iU/L[28] or if
the attending clinician suspected paracetamol toxicity, following which the intervention would
be unblinded to allow consideration of the administration of intravenous n-acetyl cysteine.
Additional stopping criteria included the development of clinically significant hypotension
(see safety outcomes below for definitions).
Core body temperature was measured hourly using an intravesical temperature probe dur-
ing the study intervention period unless specific contraindications were present, such as con-
firmed or suspected urethral injury or renal failure (defined as urine output< 0.3mls/kg/hr for
greater than 4 hours). Alternative methods of temperature measurement included tympanic,
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axillary and nasopharyngeal measurements that were adjusted by -0.2, +0.6 and +0.3°C respec-
tively, based on previous unpublished validation data by our group (S2 Table).
We collected daily information on the use of phenytoin as an indicator of associated hepatic
enzyme induction that may result in increased paracetamol metabolism[29].
Pharmacological agents given with the intent of reducing body temperature, such as non-
steroidal anti-inflammatory drugs, were not to be used during the study intervention period,
unless directed by the treating clinician. Similarly, physical cooling interventions were not be
used for a temperature of 38°C if intracranial pressure was within normal limits. Physical
cooling could be considered for elevations of ICP above 20 mmHg despite standard manage-
ment as directed by the treating clinician[30].
Outcomes
The primary outcome was the absolute difference in mean core temperature during the
72-hour study treatment period.
Secondary outcomes were the difference in the mean number of hours on each day that
physical cooling was used; the difference in the mean arterial pressure, and the difference in the
mean intracranial pressure during the 72-hour study treatment period.
Tertiary outcomes, evaluated at day 28 after randomisation, included ICU and hospital
length of stay, and hospital mortality.
Safety outcomes included the incidence of hypotension during the 72-hour study treatment
period and the incidence of hepatic abnormalities during the first 7 days after randomisation.
Hypotension was defined as> 1 episode of either mean arterial pressure< 50 mmHg, systolic
blood pressure< 90 mmhg, or, cerebral perfusion pressure< 50 mmHg respectively, occurring
within 60 minutes of study drug administration, and occurring for> 15 minutes. Hepatic
abnormalities were defined as serum alanine transferase or aspartate aminotransferase values
above twice the upper limit of normal; bilirubin level above the normal range or an interna-
tional normalised ratio greater than or equal to 1.5.
Sample size
The initial sample size calculation was based on a similar phase II randomised controlled trial
in acute ischaemic stroke[27] that informed a predicted reduction of 0.5°C (standard deviation
[SD] 0.6°C) 72 hours after commencement of intravenous paracetamol. Allowing for a 20%
loss to follow-up (due to death or early discharge), a study population of 80 patients was
selected at a significance level of 0.05 and power of 0.90.
We chose to investigate a change in temperature of 0.5°C[2], as intravenous paracetamol
may have higher bioavailability then enteral preparations in critically ill patient populations
[31]. In addition, we considered this difference to be clinically significant based on data from a
cohort study of patients with acute stroke that reported a 5% to 10% absolute lower risk of
poor outcome with this effect[32], and a subsequent cohort study that reported a two-fold
increase in the risk of death with each 1°C elevation of temperature above 37°C[33].
Modifications of the protocol after trial commencement
In May 2011, after 3 patients had been recruited, the inclusion criteria were modified to remove
the requirement for a Glasgow Coma Score of between 3 and 8 and to extend the recruitment
period from within 48 hours of injury. The modified inclusion criteria added the requirement
for mechanical ventilation, and allowed for recruitment within 72 hours of injury. These
changes were made to improve the generalisability of the study and to increase recruitment.
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In November 2012, for recruitment and funding considerations during the conduct of our
trial, we amended the analysis method to a longitudinal model to analyse all hourly tempera-
ture values during the 72-hour study treatment period. This change reduced the total sample
size to between 38 and 44 patients in total, assuming a correlation coefficient of between 0.6
and 0.7 for repeated measures within an individual participant.
Statistical methods
The statistical analysis plan was finalised prior to unblinding of the study database. Statistical
analyses were conducted at the George Institute for Global Health. The principal investigator
had full access to all of the data in the study and the writing committee takes responsibility for
the integrity of the data and the data analysis.
Discrete variables were summarised as frequencies and percentages; percentages were calcu-
lated according to the number of patients for whom data were available, and where values were
missing, the denominator was stated. Continuous variables have been summarised using stan-
dard measures of central tendency and dispersion, either mean and SD, or median and inter-
quartile range (IQR) as appropriate.
The primary outcome, continuous secondary outcomes (mean arterial pressure and intra-
cranial pressure) and safety outcomes (liver function abnormalities) were analysed using a
repeated-measure analysis of variance with fixed effects of treatment using the baseline value
as a covariate; no imputation for missing values due to death or early discharge was done. The
dichotomous variable (hourly use of physical cooling) was presented as relative risk (RR) and
compared between groups using a generalised linear model with a binomial distribution and
logarithmic link[34]. Mortality rates at day 28 were compared using a Fisher exact test. Average
ICU and hospital length of stay were compared at day 28 using a two sample Wilcoxon rank
sums test. Statistical significance was evaluated by calculating 95% confidence intervals (95%
CI) and a p-value<0.05 was assumed to represent statistical significance.
A post hoc analysis of the primary outcome, adjusted for pre-randomisation age, GCS and
pupillary abnormalities was conducted. A sensitivity analysis of the primary outcome that




Screening and enrolment occurred between November 2010 and December 2013. Two hun-
dred and fifty seven patients were evaluated for trial eligibility and 41 patients were randomised
(Fig 1).
There was no difference in baseline characteristics between the two groups (Table 1). The
mean body temperature at randomisation in the paracetamol and saline group was 37.3±0.8°C
and 37.6±0.6°C respectively.
Process measures
The median (IQR) number of doses of study drug received by the paracetamol and control
groups was 18 (17–18) and 18 (16–18) respectively (P = 0.85); 33/41 (80%) of patients received
15 or more doses of study drug: 17/21 in the paracetamol group and 16/20 in the saline group
(S3 Table).
During the study intervention period, 2798 temperature measurements were made in 41 pa-
tients (median 73 [67–76] per patient). Five patients were unable to have intravesical temperature
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Fig 1. Flow of participants through the trial.
doi:10.1371/journal.pone.0144740.g001
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measurements for some or all of the study intervention period: of these, 2 had tympanic or axillary
temperature measurements and 1 had nasopharyngeal temperature measurements.
In the paracetamol group 13/20 patients underwent intracranial pressure monitoring, com-
pared to 15/20 patients in the control group.
Table 1. Demographic characteristics of patients at and prior to randomisation.
Paracetamol* (n = 21) Saline* (n = 20) Total (n = 41)
DEMOGRAPHICS
Age/years: mean (SD) 33 (16) 33 (18) 33 (17)
Male Sex: n (%) 18/21 (86) 15/20 (75) 33/41 (81)
Weight/kg: mean (SD) 83 (10) 83 (18) 83 (14)
INJURY CHARACTERISTICS
Type of injury: n/N (%) Motor Vehicle 11/21 (51) 11/20 (55) 22/41 (54)
Fall 4/21 (19) 7/20 (35) 11/41 (27)
Other 6/21 (29) 2/20 (10) 8/41 (20)
Major extracranial injury: n/N (%) 5/19 (26) 8/18 (44) 13/37 (35)
Time from Injury to ED/hours: median (IQR) 1:47 (0.50–3.26) 2:42 (0.59–3.33) 2.09 (0.59–3.26)
Time from ED to ICU/hours: median (IQR) 5:35 (3:59–8.43) 4:25 (3:24–9.05) 5:25 (3:43–8:54)
ICU admission source n/N (%) Emergency department 5/21 (24) 7/20 (35) 12/41 (29)
Operating theatre 12/21 (57) 13/20 (65) 25/41 (61)
Other 4/21 (19) 0/20 (0) 4/41 (10)
PRE-RANDOMISATION CHARACTERISTICS
Time: ICU admission to randomisation/hours: median (IQR) 33:40 (22:00–42:45) 36:59 (16:45–53:44) 34:17 (19:27–52:30)
Temperature/°C: Median (IQR) 37.6 (36.9–37.9) 37.4 (37.2–38.0) 37.5 (37.0–38.0)
Mean (SD) 37.3 (0.8) 37.6 (0.6) 37.4 (0.7)
Mean arterial pressure/mmHg: mean (SD) 91 (12) 88 (9) 90 (10)
Vasopressor n/N (%) 5/21 (24) 6/20 (30) 11/41 (27)
Pupil responsive to light n/N (%) Right 18/21 (86) 20/20 (100) 38/41 (93)
Left 18/21 (86) 20/20 (100) 38/41 (93)
GCS: median (IQR) 6 (3–7) 7 (3–9) 6 (3–7)
ICU admission APACHE II score, mean (SD) 18 (4) 17 (6) 17 (5)
Alanine aminotransferase U/l: median (IQR) 37 (28–73) 34 (21–47) 36 (25–63)
Bilirubin: median (IQR) 11 (9–19) 10 (7–15) 11 (9–18)
International Normalised Ratio: median (IQR) 1.2 (1.1–1.3) 1.2 (1.1–1.2) 1.2 (1.1–1.3)
Osmotic intervention n/N (%) 10/21 (48) 7/19 (37) 17/40 (43)
Use of hyperventilation n/N (%) 5/21 (24) 1/19 (5) 6/40 (15)
Use of thiopentone n/N (%) 0 (0) 0 (0) 0 (0)
Neurosurgical Operative intervention n/N (%) 9/19 (48) 11/19 (58) 20/38 (53)
Evacuation of mass lesion (%) 7/20 (35) 9/20 (45) 16/40 (40)
Decompressive craniectomy (%) 6/20 (30) 5/20 (25) 11/40 (28)
Use of extracorporeal circuit n/N (%) 1/21 (5) 0/20 (0) 1/41 (2)
Use of steroid n/N (%) 2/21 (10) 0/20 (0) 1/41 (5)
*There were no signiﬁcant differences between study groups in any of the measured baseline characteristics.
A severity of illness score using the Acute Physiology and Chronic Health Evaluation II (APACHE II[39]) was calculated with information from the ﬁrst 24
hours after ICU admission. Scores on the APACHE II range from 0 to 71, with higher scores indicating more severe disease and a higher risk of death.
Abbreviations: IQR: interquartile range; SD: standard deviation; ED: emergency department; ICU: intensive care unit; GCS: Glasgow coma score; ICP:
intracranial pressure.
doi:10.1371/journal.pone.0144740.t001
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Phenytoin was used in 14/21 and 19/20 patients in the paracetamol and saline groups
respectively.
Outcomes
The mean ± SD temperature during the study period was 37.4±0.5°C and 37.7±0.4°C in the
paracetamol and saline groups respectively (mean difference -0.3°C; 95%CI -0.6 to 0.0;
P = 0.09) (Fig 2 and S4 Table).
The mean ± SD number of hours per day that physical cooling was used during study treat-
ment was 2.2 ± 0.7 hours in the paracetamol group and 3.8 ± 1.2 hours in the saline group (RR
0.6; 95%CI 0.3 to 1.3; P = 0.17) (Table 2). The mean arterial pressure during study treatment
Fig 2. Primary outcome: mean and standard deviation (SD) temperature plotted against time during
the study intervention period for paracetamol (n = 21) and saline control group (n = 2). For clarity, data
are presented as mean and upper SD for saline, and mean and lower SD for paracetamol, at 4-hourly time-
points following the time of randomisation (Rando), and until 4 hours after the final dose of study drug.
doi:10.1371/journal.pone.0144740.g002









Mean temperature/°C (SD) 37.4 (0.5) 37.7 (0.4) -0.3 (-0.6 to 0.0)* 0.09
(†Adjusted) Mean temperature/°C (SD): 37.5 (0.9) 37.8 (0.9) -0.3 (-0.7 to 0.0)* 0.09
Intracranial pressure/mmHg (SD) 12.8 (1.0) 14.4 (0.9) -1.5 (-4.4 to 1.3)* 0.2669
Mean arterial pressure/mmHg (SD) 90.4 (1.6) 93.2 (1.6) -2.8 (-7.3 to 1.8)* 0.2260
Number of hours/day that physical cooling was
used (SD)
2.2 (0.7) 3.8 (1.2) 0.6 (0.3 to 1.3)** 0.1726
† Adjusted for age, GCS and pupillary response and with baseline temperature as a covariate.
* Mean difference.
** Relative risk.
Abbreviations: CI: conﬁdence intervals; SD: standard deviation; GCS: Glasgow coma score.
doi:10.1371/journal.pone.0144740.t002
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was 90.4 ± 1.6 and 93.2 ± 1.6 mmHg in the paracetamol and saline groups respectively (mean
difference -2.8 mmHg; 95% CI -7.3 to 1.8; P = 0.23). The mean intracranial pressure during
study treatment was 12.8 ± 1.0 and 14.4 ± 0.9 mmHg in the paracetamol and 0.9% saline
groups respectively (mean difference -1.5mmHg; 95% CI -4.4 to 1.3; P = 0.27).
The overall day-28 mortality rate was 9.8% (4/41): 14.3% (3/21) in the paracetamol group
and 5% (1/20) in the saline group (P = 0.32) (Table 3).
After post hoc adjustment for pre-randomisation age, GCS and pupillary abnormalities, the
mean temperature of the paracetamol and saline groups was 37.5°C (SD 0.9) and 37.8°C (SE
0.8) respectively (mean difference -0.3°C; 95% CI -0.7 to 0.0; P = 0.09). A sensitivity analysis
excluding patients that were unable to have intravesical temperature measurement for the
duration of study intervention did not alter the interpretation of the primary outcome.
Safety
There was no episode of systemic or cerebral hypoperfusion in either group and no difference
in the incidence of hepatic abnormalities (Table 4 and S5 Table) between the two study groups.
Discussion
Summary of principal findings
The early, routine intravenous administration of 6 grams/day of paracetamol did not signifi-
cantly reduce core temperature in patients with TBI compared to placebo.
Strengths
Wemitigated the risk of ascertainment bias through randomisation, allocation concealment,
and masking of treatment assignments. The primary outcome was not subject to observer bias.
We finalised the statistical analysis plan and conducted all analyses before unmasking of study
groups assignments.
Table 3. Tertiary outcomes.
Paracetamol (n = 21) Saline (n = 20) Total (n = 41) P-value
Intensive care length of stay (days): median (IQR) 13.0 (7.0–15.0) 12.0 (6.0–15.0) 12.0 (6.0–15.0) 0.84
Hospital length of stay (days): median (IQR) 36.5 (23.0–48.0) 29.0 (20.0–41.0) 32.0 (22.5–47.0) 0.34
Hospital mortality (%) 3/ 21 (14.3) 1/ 20 (5.0) 4/ 41 (9.8) 0.61
Abbreviations: IQR: inter-quartile range.
doi:10.1371/journal.pone.0144740.t003
Table 4. Safety outcomes: incidence of abnormalities of alanine transferase, aspartate aminotransferase, bilirubin and the international normal-
ised ratio.
Paracetamol (n = 21) Saline (n = 20) Total (n = 41) P-value
Abnormal alanine transferase (%) 8/ 21 (38.1%) 7/ 20 (35.0%) 15/ 41 (36.6%) 1.00
Abnormal aspartate aminotransferase (%) 12/ 21 (57.1%) 12/ 20 (60.0%) 24/ 41 (58.5%) 1.00
Abnormal bilirubin (%) 7/ 21 (33.3%) 4/ 20 (20.0%) 11/ 41 (26.8%) 0.48
Abnormal international normalised ratio (%) 1/ 21 (4.8%) 0/ 20 (0.0%) 1/ 41 (2.4%) 1.00
Abnormality was deﬁned as any value > twice the upper limit of normal for ALT/AST, for bilirubin as any value above the normal range and for INR as any
value  1.5.
doi:10.1371/journal.pone.0144740.t004
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Although the number of patients was small, we obtained a substantive dataset of over 2700
temperature measurements that allowed a clear comparison between paracetamol and placebo,
thereby providing determination of the effect size.
We used a high dose and intravenous preparation of paracetamol that may influence the
generalisability of our findings, particularly in regions where intravenous paracetamol is not
widely used. However, we have reported preliminary safety data for this dose of paracetamol in
the TBI patient population and our results are supported by larger body of evidence in patients
with stroke reporting safety of this dose via the enteral route[2, 27, 35].
Our study contributes to an increasing body of literature on temperature control using para-
cetamol and physical cooling during critical illness for neurological disorders[1–5] and severe
infections[36].
Limitations
Our findings are generalisable to patients with severe traumatic brain injury that require
mechanical ventilation; these inclusion criteria were chosen to define a patient population that
would be likely to receive a complete course of study treatment.
The use of phenytoin[29] may have reduced the efficacy of paracetamol; however this was a
pragmatic study and phenytoin is used to prevent early seizures after TBI[37].
The lack of protocolisation of physical cooling in the study confounds the interpretation of
the primary outcome; the administration of paracetamol was associated with a non-significant
reduction in the use of physical cooling and this may have lead to an underestimation of the
effect of paracetamol on temperature. Future studies in this area may need to consider this
design issue. Heterogeneity in the opinions of clinicians and the absence of high quality evi-
dence precluded a strict protocolised approach in our study protocol.
Although our study was underpowered to detect an effect size of less than 0.5°C[27], it is
possible that a smaller effect may have a clinically important consequence[2, 3].
Comparison with relevant findings from other published studies
The effect of regular paracetamol on core temperature after traumatic brain injury in our study
is consistent with the effect on temperature reported in similar trials in stroke. The Acetamino-
phen In Stroke (PAIS) study compared the effect of 6g/day of enteral paracetamol to placebo in
reducing disability and death and reported that although paracetamol reduced body tempera-
ture by 0 26°C (95% CI 0 18 to 0 31), there was no significant difference in disability or death
[2]. For the subgroup of patients with a body temperature at baseline between 37 and 39°C,
there was an improvement (adjusted odds ratio 1 43; 95% CI 1 02 to 1 97), compared to
patients with a baseline temperature of 36–37°C. The PAIS-2 study was designed to further
examine this exploratory finding and recently closed recruitment in October 2014[3].
Clinical and research implications
The burden of severe TBI is increasing in low- and middle-income countries and is associated
with increased urbanisation and mechanisation but decreasing in high-income countries due
to preventative public health measures[38]. Pyrexia is common after TBI[6–10] and there is a
biological rationale that reducing pyrexia after TBI may have the potential to improve patient-
centred outcomes[2, 8, 10–16]. Clinical trials are needed to evaluate if interventions given to
avoid pyrexia reduce disability and death after TBI[17–21].
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Conclusion
The early administration of 6g/day of intravenous paracetamol did not result in a significant
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